July 16, 2022
1 min watch
Source/Disclosures
Published by:
Source:
Healio Interviews
Disclosures:
Lurker reports being the CEO of EyePoint Pharmaceuticals.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW YORK — In this Healio Video Perspective from the ASRS meeting, Nancy Lurker, CEO of EyePoint Pharmaceuticals, announces the 12-month results from the DAVIO clinical trial of EYP-1901 for wet age-related macular degeneration.
Discussion about this post